Cargando…

Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer

SIMPLE SUMMARY: Breast cancer emergencies have become a rapidly evolving field in medicine during the last ten years. Carcinogenesis is a multiparametric process that involves diverse factors such as genetic, environmental, or aging. Recent research that elucidates the tumor biology and molecular pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Chia-Jung, Tzeng, Yen-Dun Tony, Chiu, Yi-Han, Lin, Hung-Yu, Hou, Ming-Feng, Chu, Pei-Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232221/ https://www.ncbi.nlm.nih.gov/pubmed/34198652 http://dx.doi.org/10.3390/cancers13122978

Ejemplares similares

Multi-Omics Reveals the Immunological Role and Prognostic Potential of Mitochondrial Ubiquitin Ligase MARCH5 in Human Breast Cancer
por: Chu, Pei-Yi, et al.
Publicado: (2021)

Integrated analysis of pivotal biomarker of LSM1, immune cell infiltration and therapeutic drugs in breast cancer
por: Tzeng, Yen‐Dun Tony, et al.
Publicado: (2022)

Advances in Understanding Mitochondrial MicroRNAs (mitomiRs) on the Pathogenesis of Triple-Negative Breast Cancer (TNBC)
por: Lin, Hung-Yu, et al.
Publicado: (2021)

Downregulation of ATP binding cassette subfamily a member 10 acts as a prognostic factor associated with immune infiltration in breast cancer
por: Chu, Pei-Yi, et al.
Publicado: (2022)

Molecular characteristics of recurrent triple-negative breast cancer
por: TSAI, CHUNG-HSIN, et al.
Publicado: (2015)

Kinome-Wide siRNA Screening Identifies DYRK1B as a Potential Therapeutic Target for Triple-Negative Breast Cancer Cells
por: Chang, Chia-Che, et al.
Publicado: (2021)

Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis
por: Su, Jung-Chen, et al.
Publicado: (2016)

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021)

CIP2A is a target of bortezomib in human triple negative breast cancer cells
por: Tseng, Ling-Ming, et al.
Publicado: (2012)

Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype
por: Shao, Fangyuan, et al.
Publicado: (2017)

Kinome-Wide siRNA Screening Identifies Src-Enhanced Resistance of Chemotherapeutic Drugs in Triple-Negative Breast Cancer Cells
por: Tzeng, Yen-Dun Tony, et al.
Publicado: (2018)

CAPER as a therapeutic target for triple negative breast cancer
por: Campbell, Mallory C., et al.
Publicado: (2018)

Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer
por: Ryu, Won-Ji, et al.
Publicado: (2021)

Ferroptosis and triple-negative breast cancer: Potential therapeutic targets
por: Xu, Na, et al.
Publicado: (2022)

MZF-1/Elk-1 interaction domain as therapeutic target for protein kinase Cα-based triple-negative breast cancer cells
por: Lee, Chia-Jen, et al.
Publicado: (2016)

Recent advances in targeted strategies for triple-negative breast cancer
por: Zhu, Shuangli, et al.
Publicado: (2023)

Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness
por: Lee, Kha-Liang, et al.
Publicado: (2019)

Targeting Triple Negative Breast Cancer Stem Cells by Heat Shock Protein 70 Inhibitors
por: Tsai, Chia-Hung, et al.
Publicado: (2022)

New Insights into the Role of Inflammation in the Pathogenesis of Atherosclerosis
por: Wu, Meng-Yu, et al.
Publicado: (2017)

Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2016)

Immune checkpoints: A therapeutic target in triple negative breast cancer
por: Chawla, Akhil, et al.
Publicado: (2014)

Therapeutic potential of ERK5 targeting in triple negative breast cancer
por: Ortiz-Ruiz, María Jesús, et al.
Publicado: (2014)

Targeting Senescence as a Therapeutic Opportunity for Triple-Negative Breast Cancer
por: de Paula, Bruno, et al.
Publicado: (2023)

Correction: Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2017)

A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women
por: Tseng, Ling-Ming, et al.
Publicado: (2017)

Triple-Negative Breast Cancer
por: Chu, Quyen D., et al.
Publicado: (2012)

Differential gene expression and AKT targeting in triple negative breast cancer
por: Lin, Feng-Mao, et al.
Publicado: (2019)

Cripto-1 as a novel therapeutic target for triple negative breast cancer
por: Castro, Nadia P., et al.
Publicado: (2014)

Molecular Mechanisms and Emerging Therapeutic Targets of Triple-Negative Breast Cancer Metastasis
por: Neophytou, Christiana, et al.
Publicado: (2018)

Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy
por: Yang, Ruoning, et al.
Publicado: (2022)

Stemness signature and targeted therapeutic drugs identification for Triple Negative Breast Cancer
por: Gul, Samina, et al.
Publicado: (2023)

Integration of radiogenomic features for early prediction of pathological complete response in patients with triple-negative breast cancer and identification of potential therapeutic targets
por: Zhang, Ying, et al.
Publicado: (2022)

RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer
por: Weng, Tian-Hao, et al.
Publicado: (2020)

Varlitinib Downregulates HER/ERK Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells
por: Liu, Chun-Yu, et al.
Publicado: (2019)

Fish Oil and Selenium with Doxorubicin Modulates Expression of Fatty Acid Receptors and Selenoproteins, and Targets Multiple Anti-Cancer Signaling in Triple-negative Breast Cancer Tumors
por: Guo, Chih-Hung, et al.
Publicado: (2022)

The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2017)

Triple-Negative Breast Cancer: Adjuvant Therapeutic Options
por: Gucalp, Ayca, et al.
Publicado: (2011)

Therapeutic landscape in mutational triple negative breast cancer
por: Shi, Yaqin, et al.
Publicado: (2018)

β1 Integrin as a Prognostic and Predictive Marker in Triple-Negative Breast Cancer
por: Yin, Hsin-Ling, et al.
Publicado: (2016)

BC200 overexpression contributes to luminal and triple negative breast cancer pathogenesis
por: Barton, Maria, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9nmq05v57ua5u2q676534u89ic